Mangalam Drugs and Organics share news and announcements

NSE: MANGALAMBSE: 532637Pharmaceuticals & BiotechnologySmall Cap

₹28.65₹0.92 (3.11%)BSE ₹28.00

Share price at the NSE close on 23 Oct 2026. Previous close ₹29.57.

52-week range of traded prices to 23 Oct 2026

₹22.80Low, 29 Dec 2025₹71.99High, 23 Oct 2025

Under NSE's long-term additional surveillance, stage I, on the list for 23 Oct 2026. The exchange puts a share here when its price has moved unusually, and trading in it carries extra conditions.

Market cap: ₹45 Cr3,423rd largest listed
P/E: Lossover the last 12 months
P/B: 0.4
Dividend yield: Nonein the last 12 months
ROE: −30.3%
ROCE: −12.9%
Debt to equity: 1.02
Volume, NSE: 19,55176.4% delivered

Mangalam Drugs and Organics share news and announcements

527 announcements, routine notices left out, newest first. Page 8 of 11.

Feb 2018
- 1 Feb · Board meeting
  Inter-alia to consider and approve the following: 1. To approve, consider and take on record the Unaudited Financial Results along with Limited review report of the company for the quarter & nine months ended December 31, 2017. 2. Any other matters with the permission of the chair. (opens in a new tab)
Dec 2017
- 28 Dec · Legal
  Significant increase in volume has been observed in Mangalam Drugs And Organics Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Mangalam Drugs And Organics Limited has submitted their response. (opens in a new tab)
  The exchange asked on 27 Dec 2017
- 12 Dec · Corporate action
  Company has fixed Record Date as December 22, 2017 for the purpose of Interim dividend (opens in a new tab)
- 12 Dec · Dividend
  Board of Directors at its Meeting held on December 12, 2017 has declared an interim dividend of 50 paise (Fifty paise only) per equity share having face value of Rs.10/- each (i.e. 5%) on the equity shares of the company for the financial year 2017-18. (opens in a new tab)
- 7 Dec · Board meeting
  Inter-alia, to consider and declare the interim dividend for the financial year 2017-18. (opens in a new tab)
Nov 2017
- 20 Nov · Management
  Change in Director(s) of the company. (opens in a new tab)
- 20 Nov · Results
  Financial results for the period ended September 30, 2017. (opens in a new tab)
- 20 Nov · Board meeting
  Outcome of Board Meeting held on November 20, 2017. (opens in a new tab)
- 9 Nov · Board meeting
  Inter-alia to consider and approve the following: 1. To approve, consider and take on record the Unaudited Financial Results along with Limited review report of the company for the quarter & half year ended September 30, 2017. 2. Any other matters with the permission of the chair. (opens in a new tab)
Sep 2017
- 28 Sep · Meeting
  Copy Srutinizers report of Annual General Meeting held on September 26, 2017. Further, the company has informed the Exchange regarding voting results. (opens in a new tab)
- 27 Sep · Meeting
  Proceedings of Annual General Meeting held on September 26, 2017 (opens in a new tab)
- 15 Sep · Updates
  The Company is pleased to inform you that we have recently received the final approval from WHO for the drug Emtricitabine. (opens in a new tab)
- 1 Sep · Meeting
  Notice of Annual General Meeting to be held on September 26, 2017 (opens in a new tab)
Aug 2017
- 21 Aug · Meeting
  Register of Members and Share Transfer Books of the Company shall remain closed from September 20, 2017 to September 26, 2017(both days inclusive) for the purpose of Annual General Meeting of the Company is scheduled to be held on September 26, 2017 (opens in a new tab)
- 11 Aug · Results
  Financial results for the period ended June 30, 2017. (opens in a new tab)
- 11 Aug · Board meeting
  Outcome of Board Meeting held on August 11, 2017. (opens in a new tab)
Jul 2017
- 31 Jul · Board meeting
  11-Aug-2017 : The Company had Informed the Exchange regarding the Board Meeting Scheduled to be held on August 04, 2017 inter-alia to consider and approve the following: (1) To approve, consider and take on record the Unaudited Financial Results along with Limited review report of the company for the quarter ended June 30, 2017 2. Any other matters with the permission of the chair. the company has now inform the exchange that due to unavailability of the quorum the meeting of the Board of Directors is postponed and Rescheduled August 11, 2017. (opens in a new tab)
- 27 Jul · Board meeting
  Inter-alia to consider and approve the following: (1) To approve, consider and take on record the Unaudited Financial Results along with Limited review report of the company for the quarter ended June 30, 2017 2. Any other matters with the permission of the chair. (opens in a new tab)
May 2017
- 25 May · Updates
  Company has recently received the final approval of WHO-Geneva for its Plant on Unit-2 situated at Plot No. 1203, 3rd Phase, G.I.D.C, Vapi-396195 . (opens in a new tab)
- 8 May · Results
  Financial results for the period ended March 31, 2017. (opens in a new tab)
- 8 May · Board meeting
  Board of Directors at their Meeting held on May 08, 2017 , inter alia transacted the following business: 1. The Board of Directors considered and took on record Audited Financial Results for the quarter and year ended March 31, 2017. 2. Other Business transacted with permission of chair. (opens in a new tab)
Apr 2017
- 28 Apr · Board meeting
  Inter-alia to consider, approve and take on record the Audited Financial Results/Statement of the company for the quarter and year ended March 31, 2017 and any other matters with the permission of the Chair. Further the Trading Window for the purpose of the said Board Meeting will remain closed from April 29, 2017 and would open 48 hours after the announcement of financial results to the public. (opens in a new tab)
Mar 2017
- 6 Mar · Updates
  As per the assurance given to the shareholders by the management of the Company, we had organized a Factory visit to our Plants (Unit 1 & 2) located in the vicinity of Vapi, Gujarat on March 04, 2017 for the Shareholders who had requested to visit the Plants of the company . This Plant visit was a half day program and limited for 30 people only. (opens in a new tab)
Feb 2017
- 17 Feb · Updates
  T the company facility at Unit-2 was recently audited by WHO- Geneva and we have been issued few procedural observations. Further we shall respond to the same within stipulated time after the receipt of Audit Report. (opens in a new tab)
- 6 Feb · Results
  Financial results for the period ended December 31, 2016. (opens in a new tab)
Jan 2017
- 30 Jan · Board meeting
  Inter-alia to consider and approve the following:1) To approve, consider and take on record the Unaudited Financial Results of the company for the quarter and nine months ended December 31, 20162) Any other matters with the permission of the chair. (opens in a new tab)
Nov 2016
- 10 Nov · Results
  Financial results for the period ended September 30, 2016. (opens in a new tab)
- 3 Nov · Rating
  Credit Rating (opens in a new tab)
- 2 Nov · Board meeting
  Inter-alia to consider and approve the following: 1)To approve, consider and take on record the Unaudited Financial Results of the company for the quarter and half year ended 30th September, 2016 2) Any other matters with the permission of the chair. Further, in accordance with Code of Conduct for Prevention of Insider Trading framed by the Company pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015, the trading window for dealing in the securities of the Company will be closed for all directors, officers and designated employees of the Company from November 02, 2016 and would open 48 hours after the announcement of financial results to the public. (opens in a new tab)
Oct 2016
- 28 Oct · Meeting
  Minutes of Annual General Meeting of the Company held on September 30, 2016. (opens in a new tab)
- 3 Oct · Regulation 44(3) of SEBI (LODR), Reg., 2015
  Details of voting results of the Annual General Meeting of the Company held on September 30, 2016 along with the Scrutinizer's Report. (opens in a new tab)
- 1 Oct · Meeting
  Proceedings of the Annual General Meeting of the Company held on September 30, 2016. (opens in a new tab)
Sep 2016
- 6 Sep · Meeting
  Notice of the Annual General Meeting of the Members of the Company will be held on September 30, 2016. (opens in a new tab)
Aug 2016
- 24 Aug · Business
  Company 's Plant on Unit-2 situated at Vapi has commenced its Trial Operations. (opens in a new tab)
- 23 Aug · Corporate action
  Mangalam Drugs And Organics Limited had informed the Exchange that the Company has fixed Book Closure from September 24, 2016 to September 29, 2016 for the purpose of Annual General Meeting of the Company scheduled to be held on September 29, 2016. The Company has now informed the Exchange that The Board of Directors of the Company has decided to postpone the date of Annual General Meeting of the company to be held on September 30, 2016. Further, the Register of Members and the Share Transfer Books of the Company shall remain closed from September 24, 2016 to September 30, 2016 (both days inclusive) for the purpose of AGM. (opens in a new tab)
- 22 Aug · Meeting
  Register of Members and Share Transfer Books of the Company shall remain closed from September 23, 2016 to September 29, 2016 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 29, 2016. (opens in a new tab)
- 1 Aug · Results
  Standalone financial results along with the Limited Review Report for the period ended June 30, 2016. (opens in a new tab)
Jul 2016
- 23 Jul · Board meeting
  Inter-alia to consider and approve the following: 1. To approve, consider and take on record the Unaudited Financial Results of the company for the quarter ended June 30, 2016 2. Any other matters with the permission of the chair. (opens in a new tab)
Jun 2016
- 10 Jun · Board meeting
  Board of Directors at their Meeting held on June 10, 2016 has inter alia transacted the following business : Approved the allotment of balance 14,50,000 Equity Shares of Rs. 10/- each at a premium of Rs. 55/- per share pursuant to exercise of right for conversion of remaining 14,50,000 warrants into equity shares to the promoter group on preferential basis, upon the receipt of balance consideration amount on it . (opens in a new tab)
- 3 Jun · Corrigendum
  Corrigendum to the disclosure under Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 dated May 16, 2016 w.r.t. filing of audited financial results (standalone) for the quarter and year ended March 31, 2016. (opens in a new tab)
- 2 Jun · Board meeting
  10-Jun-2016 : The Company had informed the Exchange regarding the Board Meeting to be held on June 06, 2016 to inter alia consider and approve the allotment of 14,50,000 Equity Shares on conversion of remaining 14,50,000 Share Warrants which were allotted on preferential basis to Shri JB Pharma LLP, ( Promoter or Proposed Allottee ) on September 28, 2015 and the issue of which was approved by the shareholders at Annual General Meeting of the Company held on September 3, 2015., in Compliance with SEBI (ICDR) Regulations, 2009, Companies Act, 2013 and other applicable laws, rules and regulations. The company has now inform the exchange that due to unavoidable circumstances the meeting of Board of Directors is postponed and re-scheduled to June 10, 2016. (opens in a new tab)
May 2016
- 26 May · Board meeting
  To inter alia consider and approve the allotment of 14,50,000 Equity Shares on conversion of remaining 14,50,000 Share Warrants which were allotted on preferential basis to Shri JB Pharma LLP, ( Promoter or Proposed Allottee ) on September 28, 2015 and the issue of which was approved by the shareholders at Annual General Meeting of the Company held on September 3, 2015., in Compliance with SEBI (ICDR) Regulations, 2009, Companies Act, 2013 and other applicable laws, rules and regulations. (opens in a new tab)
- 24 May · Updates
  Investor Presentation May 2016. (opens in a new tab)
- 16 May · Management
  Board of Directors at its meeting held on May 16, 2016 has approved the following changes in the directorate : (1) Approved the appointment of Ms. Anuradha Sukhani as Additional Director on the Board of the Company with effect from May 16, 2016. She will be Non executive Independent Director of the Company; (2) Approved the resignation of Ms. Meenal Sukhani, Director of the company with effect from the closure of Business hours on May 16, 2016. The Board has expressed its sincere thanks and placed on record its deep sense of appreciation and gratitude for the valuable services rendered by her during her tenure. (opens in a new tab)
- 16 May · Results
  Standalone financial results along with the Auditors Report for the period ended March 31, 2016. (opens in a new tab)
- 16 May · Board meeting
  Board of Directors at their Meeting held on May 16, 2016 has transacted the following business:(1) Appointment of Ms. Anuradha Sukhani as Additional Director on the Board of the Company with effect from May 16, 2016. She will be Non executive Independent Director of the Company.(2) Accepted the Resignation of Ms. Meenal Sukhani, Director of the company with effect from the closure of Business hours on May 16, 2016.(3) Other Business transacted with permission of chair. (opens in a new tab)
- 6 May · Board meeting
  Inter-alia to consider, approve and take on record the following:1. To consider and take on record the Audited Financial Results for the quarter and year ended March 31, 20162. Any other matters with the permission of the chair (opens in a new tab)
Mar 2016
- 30 Mar · Meeting Updates
  Independent Directors at their seperate Meeting held on March 30, 2016 , inter-alia transacted the following business:1. Reviewed the performance of non-independent directors and the Board as a Whole;.2. Reviewed the performance of the Chairperson of the Company, taking into account the views of executive directors and non-executive directors.3. Assessed the quality, quantity and timeliness of flow of Information between the Company management and the Board that is necessary for the Board to effectively and reasonably perform their duties. (opens in a new tab)
- 26 Mar · Meeting Updates
  Meeting of the Independent Directors of the Company will be held on March 30, 2016 inter-alia to consider and take on record the following: 1. To review the performance of non-independent directors and the board of directors as a whole; 2. review the performance of the chairperson of the listed entity, taking into account the views of executive directors and non-executive directors; 3. assess the quality, quantity and timeliness of flow of information between the management of the listed entity and the board of directors that is necessary for the board of directors to effectively and reasonably perform their duties
Jan 2016
- 19 Jan · Results
  In continuation to their filing dated January 14, 2016, wherein they had uploaded unaudited financial results of the company for the quarter and nine months ended December 31, 2015. A typing error has come to their notice in Notes section (Note No. 4). Enclosed is the Corrigendum. (opens in a new tab)

Mangalam Drugs and Organics share news and announcements

Feb 2018

Dec 2017

Nov 2017

Sep 2017

Aug 2017

Jul 2017

May 2017

Apr 2017

Mar 2017

Feb 2017

Jan 2017

Nov 2016

Oct 2016

Sep 2016

Aug 2016

Jul 2016

Jun 2016

May 2016

Mar 2016

Jan 2016